Mometasone: Nursing Drug Guide, Route & Product Safety & NCLEX Review
Mometasone furoate ships as NASONEX (intranasal), ASMANEX TWISTHALER (inhaled maintenance), and ELOCON (topical)—each with different dosing, technique, and danger signals. The highest-stakes nursing error is grabbing the wrong bottle or treating acute wheeze or sudden congestion with a maintenance steroid instead of rescue therapy or escalation.
Read the MAR product name and route before every dose. ASMANEX TWISTHALER is maintenance asthma therapy—not for acute bronchospasm; pair with a prescribed rescue short-acting beta2-agonist (e.g., albuterol). After inhaled doses, patients must rinse the mouth with water without swallowing to reduce oral candidiasis. NASONEX is intranasal only—not for oral inhalation or skin. ELOCON cream is topical only; avoid face, groin, and underarms unless directed, and do not use occlusive dressings unless prescribed—systemic absorption can suppress the HPA axis. If breathing worsens despite rescue therapy or nasal symptoms fail to improve after 2 weeks of intranasal use, escalate per labeling.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Match the ordered product, route, and indication—NASONEX spray in the nose, ASMANEX powder inhaled, ELOCON on skin only. For inhaled maintenance, confirm rescue bronchodilator access and rinse-after-dose teaching. For topical use, verify thin application, no unauthorized occlusion, and prescriber limits on duration and body surface. Rising rescue use, epistaxis, or HPA suppression cues need same-shift follow-up.
Most common brand names
Mometasone furoate is sold in separate prescription products with different routes. Always verify the MAR product name, strength, and administration route before every dose.
- NASONEX — intranasal metered spray 50 mcg per actuation for allergic rhinitis, nasal congestion, and nasal polyps (indications vary by age)
- ASMANEX TWISTHALER — dry-powder inhalation for maintenance asthma prophylaxis in patients ≥4 years (not for acute bronchospasm)
- ELOCON — topical cream, ointment, lotion, or solution 0.1% for corticosteroid-responsive dermatoses in patients ≥2 years
Do not substitute NASONEX for ASMANEX, apply ELOCON inside the nose, or use intranasal spray on skin. Reconcile home products at admission—patients often carry multiple mometasone bottles.
Why we give it — Indications
Indications depend entirely on the ordered product—mometasone furoate is delivered intranasally, by inhalation, or topically with separate labeling for each.
| Product / route | Indications (per reviewed labeling) |
|---|---|
| NASONEX — intranasal | Nasal symptoms of seasonal and perennial allergic rhinitis (adults and children ≥2 y); nasal congestion with seasonal allergic rhinitis; prophylaxis of seasonal allergic rhinitis (adults/adolescents ≥12 y); nasal polyps (adults ≥18 y) |
| ASMANEX TWISTHALER — inhaled | Maintenance treatment of asthma as prophylactic therapy in patients ≥4 years—not for relief of acute bronchospasm or in children <4 years |
| ELOCON — topical | Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., eczema, atopic dermatitis) in patients ≥2 years |
| Limitation — not immediate relief | Intranasal and inhaled mometasone are maintenance therapies; inhaled product is not a bronchodilator. Acute asthma symptoms require a short-acting beta2-agonist per ASMANEX labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Mometasone furoate is a synthetic corticosteroid with anti-inflammatory activity at the site of application—nasal mucosa, airways, or skin. It does not provide immediate bronchodilation or decongestion. ASMANEX TWISTHALER labeling notes maximum benefit may not occur for 1 to 2 weeks or longer. NASONEX may require regular daily use before full benefit; seasonal prophylaxis may begin 2 to 4 weeks before pollen season per labeling.
Dosing overview
Dosing is product-specific. Confirm which formulation is ordered before teaching or administering.
Missed dose: NASONEX patient labeling advises taking a missed dose when remembered but not doubling the daily dose. Other formulations: not specified in the reviewed prescribing information—reinforce scheduled adherence without extra doses unless prescriber directs.
Before you give it — Safety check
Pretreatment checks
- Match MAR product to correct route: intranasal spray, dry-powder inhaler, or topical—never interchange
- For ASMANEX: confirm rescue short-acting beta2-agonist available; assess wheezing, shortness of breath, and rescue frequency
- For NASONEX: inspect nasal mucosa for bleeding, ulceration, or fungal infection; confirm spray technique and pump priming status
- For ELOCON: verify affected area, body surface area, duration of use, and no unauthorized occlusive dressings or diaper occlusion on treated skin
- Screen for milk protein allergy before ASMANEX (contains lactose with trace milk proteins); review strong CYP3A4 inhibitors on MAR
Contraindications
- Hypersensitivity to mometasone furoate or any ingredient in the specific product
- ASMANEX: known hypersensitivity to milk proteins; primary treatment of status asthmaticus or acute asthma requiring intensive measures
- NASONEX: not specified beyond hypersensitivity in reviewed labeling—avoid use with untreated localized nasal fungal infection per warnings
- ELOCON: hypersensitivity to formulation components; do not use in children <2 years
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, itraconazole, others) | May increase systemic mometasone exposure; ASMANEX labeling advises caution; NASONEX notes ketoconazole may increase plasma concentrations | Notify prescriber/pharmacist if inhibitor started; monitor for hypercorticism, adrenal suppression, and glucose changes |
| Systemic corticosteroids | Adrenal insufficiency reported when transferring from oral steroids to inhaled ICS; ASMANEX requires slow prednisone taper (e.g., 2.5 mg/week reduction after ≥1 week of ICS) | Never stop oral steroids abruptly; monitor fatigue, nausea, hypotension |
| Duplicate corticosteroids across routes | Additive systemic and local effects (e.g., NASONEX plus ASMANEX plus extensive ELOCON) | Reconcile all mometasone and other steroid products at medication reconciliation |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Follow medication administration rights and the specific product labeling for route and technique.
NASONEX (intranasal)
- Intranasal route only—do not spray into mouth or eyes
- Prime pump with 10 actuations before first use; if unused >1 week, reprime with 2 actuations until fine spray appears
- Gently blow nose, aim away from nasal septum, sniff gently; avoid blowing nose 15 minutes after use per patient labeling
- Adult supervision required for children using the device
ASMANEX TWISTHALER (inhaled)
- Oral inhalation only—instruct rapid deep inhalation per device training; cap-activated dry powder (not an MDI—do not shake)
- Rinse mouth with water after each dose and spit without swallowing
- Do not use for acute wheeze—administer prescribed rescue beta2-agonist when immediate relief is needed
ELOCON (topical)
- Apply thin film once daily to affected skin only; wash hands after application unless hands are the treated area
- Do not use on face, groin, or underarms unless directed; avoid eyes, mouth, and vagina
- Do not bandage, cover, or wrap treated skin unless prescribed—diapers on treated area may act as occlusion
Swapping NASONEX for ASMANEX, using nasal spray for wheeze, or occluding topical mometasone without orders drives treatment failure, epistaxis, thrush, or HPA axis suppression. Paradoxical bronchospasm or hypersensitivity (including milk protein reactions with ASMANEX) requires discontinuation and prescriber follow-up per labeling.
Expected therapeutic response
- Intranasal: Gradual improvement in nasal congestion, sneezing, and rhinorrhea over days to weeks with daily use—not immediate decongestion
- Inhaled: Reduced asthma symptoms and rescue inhaler use over 1–2 weeks or longer—not immediate bronchodilation
- Topical: Decreased pruritus and inflammation on treated dermatoses; notify prescriber if no improvement after 2 weeks per ELOCON labeling
Red flags — Stop and act
Escalate when the wrong product is used, maintenance therapy fails, serious local or systemic toxicity appears, or rescue access is inadequate.
- Asthma episodes not responsive to usual bronchodilator doses during ASMANEX therapy—contact prescriber; oral corticosteroids may be needed per labeling
- Increased wheeze or cough immediately after inhaled dose—possible paradoxical bronchospasm; discontinue and use rescue bronchodilator
- Heavy or recurrent epistaxis, nasal septal perforation symptoms, or untreated nasal Candida—hold NASONEX and notify prescriber per warnings
- Anaphylaxis, angioedema, or severe hypersensitivity (including milk protein allergy with ASMANEX)—emergency pathway
- Signs of HPA axis suppression or adrenal insufficiency (fatigue, weakness, nausea, vomiting, hypotension)—especially with high-dose topical use, occlusion, or systemic steroid taper
- Persistent nasal or skin symptoms beyond 2 weeks without improvement—reassess diagnosis and therapy per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Epistaxis / nasal irritation (NASONEX) | Epistaxis among most common adverse reactions (≥5% in adults); nasal ulceration and septal perforation reported | Teach spray technique; inspect mucosa; hold if heavy bleeding or perforation suspected |
| Oropharyngeal candidiasis (ASMANEX) | Candida mouth/pharynx infections reported with inhaled mometasone | Rinse after doses; antifungal per prescriber; may interrupt inhaler briefly |
| Dysphonia / hoarseness | Headache, pharyngitis, and cough common with intranasal and inhaled products | Rinse after inhaled doses; document voice and throat changes |
| HPA suppression / hypercorticism | Reported with higher-than-recommended intranasal doses, prolonged topical use, occlusion, or susceptible individuals | Lowest effective dose; avoid unauthorized wrapping; monitor growth and adrenal signs in pediatrics |
| Skin atrophy (ELOCON) | Most common topical reactions include burning, pruritus, and skin atrophy per labeling | Limit duration and body surface; avoid face unless directed |
| Hypersensitivity | Anaphylaxis, angioedema, wheezing after intranasal dose, and milk protein–related reactions (ASMANEX) reported | Stop product; emergency care if indicated |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
NASONEX: Labeling states no data on acute or chronic overdose; low systemic bioavailability makes overdose unlikely to require therapy beyond observation. Chronic corticosteroid overdosage may cause hypercorticism. ASMANEX: Chronic overdosage may result in hypercorticism; acute overdose unlikely to require treatment other than observation per labeling. ELOCON: Not specified in the reviewed prescribing information for acute overdose; excessive topical use increases systemic absorption risk.
Antidote
No specific antidote is listed in the reviewed prescribing information for any mometasone formulation. Discontinue or taper gradually with prescriber guidance and treat symptomatically for systemic corticosteroid effects.
Contact local poison control or medical toxicology services for suspected excessive exposure (especially large-area topical use with occlusion) per facility protocol and local emergency guidance.
Look-alike / sound-alike and error prevention
- NASONEX vs ASMANEX vs ELOCON—same generic name, different routes; verify product name on every pass
- Mometasone vs fluticasone or budesonide—sound-alike corticosteroids; prevent duplicate therapy across MAR
- ASMANEX vs rescue albuterol—maintenance dry powder vs short-acting bronchodilator; teach-back essential
- NASONEX vs OTC decongestant sprays—corticosteroid maintenance vs short-acting vasoconstrictor; different teaching and rebound risk
- Topical mometasone vs intranasal spray—never apply nasal spray to skin or cream in the nose
- ASMANEX 110 vs 220 mcg device—delivers 100 vs 200 mcg per actuation; wrong device changes daily steroid load
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Product check | Read bottle label aloud with patient—NASONEX, ASMANEX, and ELOCON look similar in bedside bags. |
| NASONEX priming | 10 sprays before first use; reprime if unused >1 week—unprimed pump delivers subtherapeutic doses. |
| Inhaled rinse | Water rinse and spit after ASMANEX—non-negotiable for thrush prevention. |
| Topical limits | Thin film only; no plastic wrap or tight dressings unless ordered—diapers count as occlusion on infants. |
| Rescue check | For asthma patients, confirm albuterol (or ordered SABA) is present before giving ASMANEX. |
| Ask pharmacy when | Duplicate corticosteroid orders, CYP3A4 inhibitor added, or systemic steroid taper in progress. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Transfer from systemic steroids | Deaths from adrenal insufficiency reported during transfer to ICS; slow prednisone taper (e.g., 2.5 mg weekly reduction cited in labeling) and monitor for insufficiency signs. |
| Pediatrics (4–11 y) | ICS may reduce growth velocity; use lowest effective dose and monitor height routinely (stadiometry) per labeling. |
| Hepatic impairment | Mometasone furoate metabolized via CYP3A4—plasma concentrations may increase with inhibitors; monitor when hepatic function is impaired per pharmacology sections. |
| Active infections | Use caution with tuberculosis, fungal, bacterial, viral, or parasitic infections; chickenpox/measles exposure may be serious per warnings. |
| Pregnancy | Insufficient human data with ASMANEX TWISTHALER; poorly controlled asthma increases maternal/neonatal risk—maintain optimal control and adjust therapy as needed per labeling. |
| Lactation | ASMANEX: no human milk data; other inhaled corticosteroids are present in milk in small amounts per labeling. ELOCON: not known if passes into breast milk—balance benefits and risks. Consult LactMed for route-specific guidance. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory symptoms, nighttime awakenings, rescue inhaler frequency, work of breathing, and pulse oximetry per protocol
- Peak expiratory flow trends when personal best is known—decline with rising rescue use triggers prescriber call
- Oral cavity for candidiasis; voice changes or sore throat
- Growth parameters in children; signs of adrenal insufficiency during or after systemic steroid wean
Document
- Device, dose, actuations, rinse education, spacer use, and teach-back on rescue vs controller inhalers
- Rescue bronchodilator use count and prescriber notification when use increases
- Oral assessment findings and antifungal therapy if candidiasis treated
Patient teaching
- This inhaler prevents inflammation—it does not open the airways quickly; use your rescue inhaler for sudden symptoms
- Shake the MDI, prime when required, rinse your mouth with water and spit after every dose—do not swallow the rinse
- Use mometasone every day even when you feel well; stopping can allow symptoms to return
- Call your care team if you need your rescue inhaler more often, symptoms wake you at night, or breathing worsens right after a dose
- Bring all inhalers to visits so the team can check technique, device type, and counter status
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Wrong route or product for the clinical situation (e.g., NASONEX for acute wheeze, ELOCON in the nose)
- Status asthmaticus or acute severe asthma—ASMANEX is contraindicated as primary treatment
- Serious hypersensitivity, anaphylaxis, or known milk protein allergy with ASMANEX
- Active untreated nasal fungal infection or heavy epistaxis until prescriber clarifies NASONEX use
- Paradoxical bronchospasm after inhaled dose until alternative therapy is ordered
- Topical application with occlusive dressing or large body-surface coverage unless prescribed
- New strong CYP3A4 inhibitor without prescriber/pharmacist review of corticosteroid therapy
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Mometasone safety spans three routes—verify product identity at every pass, separate maintenance therapy from rescue bronchodilators, enforce rinse and topical application limits, and escalate when symptoms outpace the ordered formulation.
1. Check-before-you-give protocol
- Right patient, product, route, dose, and time—confirm NASONEX is not being used for wheeze and ELOCON is not applied intranasally
- For ASMANEX: rescue bronchodilator available; patient can distinguish devices; rinse supplies ready for teach-back
- For NASONEX: pump primed; nasal mucosa assessed; spray technique reviewed
- For ELOCON: thin application only; no unauthorized occlusion; treatment area documented
- Review duplicate corticosteroids, CYP3A4 inhibitors, and systemic steroid tapers on MAR
2. High-alert and safety badge
Not a traditional high-alert medication—treat wrong-route/product errors, controller/rescue confusion, occlusive topical use, and adrenal risk during steroid transfer as serious safety eventsHPA axis suppression and adrenal insufficiency are reported with excessive intranasal dosing, prolonged topical use with occlusion, and transfer from systemic corticosteroids without careful taper.
3. Clinical workflow: hold and question rules
- If the patient requests mometasone for sudden chest tightness, clarify which product is ordered and give rescue beta2-agonist when indicated—not NASONEX
- If intranasal symptoms persist beyond 2 weeks or asthma rescue use climbs over 2–3 days, notify prescriber same shift
- Coordinate with pharmacy when multiple mometasone products appear on the MAR or a strong CYP3A4 inhibitor is added
4. Critical teach-back questions
- “Show me which medicine you use in your nose, lungs, and on your skin.” (Patient should identify three distinct products/routes.)
- “What do you use when you cannot breathe right now?” (Patient should name the rescue bronchodilator, not NASONEX or ASMANEX.)
5. Care coordination
Pharmacist: Product differentiation teaching, duplicate corticosteroid checks, CYP3A4 review, antifungal therapy for oral or nasal candidiasis
Prescriber / respiratory team: Escalate when rescue frequency rises, epistaxis is heavy, topical treatment fails after 2 weeks, or signs suggest acute asthma deterioration or systemic adrenal insufficiency
🧠 Quick mental checklist
- Which mometasone product is due now—and is that the right route for the symptom?
- Does the asthma patient have rescue bronchodilator access and correct teach-back?
- After ASMANEX, did they rinse and spit? Any oral white patches?
- Any nosebleeds, nasal pain, or foul nasal discharge on NASONEX?
- Is topical mometasone on a reasonable area without wraps or diapers occluding it?
Mometasone NCLEX practice questions
Practice NCLEX-style clinical judgment practice for mometasone with a tabbed case (MAR, labs, vitals, nursing notes), then priority action, select-all-that-apply cues, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—match the correct product to the route and symptom, then evaluate outcomes (rescue use, rinse adherence, and symptom trends).
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- NASONEX 50 mcg, 2 sprays each nostril daily — 0900 given
- ASMANEX TWISTHALER 220 mcg, 1 inhalation inhaled QPM — due 2000
- ELOCON 0.1% cream topical daily to bilateral forearms — 0800 applied by patient
- Albuterol MDI 2 puffs q4h PRN wheeze — 1140 given (1 treatment since 0700)
- 0800: WBC 7.2 × 109/L; glucose 98 mg/dL
- 0800: AM cortisol 12 mcg/dL (facility reference range)
- No electrolyte abnormalities on morning panel
- Now: RR 24, SpO2 93% room air, HR 98, BP 118/72
- Scattered expiratory wheeze; speaks in short phrases
- Reports chest tightness started 30 minutes ago
- Nasal mucosa dry with streaked blood on tissue after morning NASONEX
- 1210: White patches on buccal mucosa; patient rinses only at bedtime
- 1215: Teach-back—patient points to ASMANEX TWISTHALER when asked which inhaler is for emergencies
- 1220: MDI counter reads 8 actuations remaining; canister feels light
- 1230: Night cough × 2 nights; rescue use 3 times since midnight
Answer key & rationale
Frequently asked questions
Can NASONEX treat sudden wheezing or an asthma attack?
No. NASONEX is for intranasal allergic rhinitis—not acute bronchospasm. ASMANEX TWISTHALER is maintenance asthma therapy and is also not for immediate relief; use a prescribed short-acting beta2-agonist for acute asthma symptoms.
When should a nurse hold mometasone and notify the prescriber?
Hold when the wrong product or route is used, for serious hypersensitivity, milk protein allergy with ASMANEX, untreated nasal fungal infection, paradoxical bronchospasm, topical occlusion without orders, or new strong CYP3A4 inhibitor without review. Clarify duplicate corticosteroid orders.
What adverse effects matter most with mometasone?
Intranasal: epistaxis and nasal irritation. Inhaled: oral candidiasis and dysphonia. Topical: skin atrophy and HPA suppression with overuse or occlusion. Systemic hypercorticism can occur with excessive dosing or drug interactions.
Is there an antidote for mometasone overdose?
No specific antidote is listed in reviewed prescribing information. Chronic overdosage may cause hypercorticism—treat with gradual withdrawal and symptomatic management per prescriber guidance.
Can ELOCON be used on the face or under bandages?
Avoid face, groin, and underarms unless directed. Do not use occlusive dressings unless prescribed—diapers on treated skin may act as occlusion and increase systemic absorption.
Why rinse after ASMANEX TWISTHALER?
Labeling reports oropharyngeal candidiasis with inhaled mometasone and instructs patients to rinse the mouth with water after administration and spit without swallowing.
References
-
U.S. National Library of Medicine. NASONEX (mometasone furoate monohydrate) nasal spray — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a06f66a9-ca36-48c6-a00d-4f614b539cdf
-
U.S. National Library of Medicine. ASMANEX TWISTHALER (mometasone furoate inhalation powder) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10b36fb2-6b0d-4f20-b197-3564d6f594b9
-
U.S. Food and Drug Administration. ELOCON (mometasone furoate) cream, 0.1% — Prescribing information. FDA label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019625s026lbl.pdf
-
Drugs and Lactation Database (LactMed). Mometasone. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK501922/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.